Evidence map›Paper›PMID 37942865›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2023

Neuro-HIV-New insights into pathogenesis and emerging therapeutic targets.

Dmitri Sviridov, Michael Bukrinsky

Open access · hybridAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Epigenetic mechanisms of HIV and opioid-induced neuropathology: Potential therapies and interventions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Role of Monocyte/Macrophages in the Pathogenesis of NeuroHIV.Results and problems in cell differentiation · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Dmitri SviridovBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-8366-3832
Michael BukrinskyThe George Washington University School of Medicine and Health Sciences, Washington, DC, USA.ORCID https://orcid.org/0000-0002-8593-0770
Baker Heart and Diabetes Institute · AUGeorge Washington University · US

Funding

SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
Supplement to R01 NS124477R01NS124477 · NINDS · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, TYOR, WILLIAM R · 2021 to 2025
$3.6M
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous systemR01MH128158 · NIMH · EMORY UNIVERSITY · PI Christina Gavegnano, Vincent Charles Marconi · 2022 to 2026
$3.2M
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular DiseaseR01HL140977 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, FITZGERALD, MICHAEL LEO · 2018 to 2021
$3.1M
Lipid raft therapy – a novel therapeutic approach for HIV-associated cardiometabolic co-morbiditiesR01HL158305 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, SVIRIDOV, DMITRI · 2021 to 2024
$2.6M
Trained immunity induced by Nef-containing extracellular vesiclesR21AI172028 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA · 2022 to 2023
$444k
NHLBI NIH HHS R01 HL140977NHLBI NIH HHS R01 HL158305NIAID NIH HHS P30 AI117970NIAID NIH HHS R21 AI172028NIMH NIH HHS R01 MH128158NINDS NIH HHS R01 NS124477
6 · The paper itself

Abstract

HIV-associated neurocognitive disorders (HAND) is a term describing a complex set of cognitive impairments accompanying HIV infection. Successful antiretroviral therapy (ART) reduces the most severe forms of HAND, but milder forms affect over 50% of people living with HIV (PLWH). Pathogenesis of HAND in the ART era remains unknown. A variety of pathogenic factors, such as persistent HIV replication in the brain reservoir, HIV proteins released from infected brain cells, HIV-induced neuroinflammation, and some components of ART, have been implicated in driving HAND pathogenesis in ART-treated individuals. Here, we propose another factor-impairment of cholesterol homeostasis and lipid rafts by HIV-1 protein Nef-as a possible contributor to HAND pathogenesis. These effects of Nef on cholesterol may also underlie the effects of other pathogenic factors that constitute the multifactorial nature of HAND pathogenesis. The proposed Nef- and cholesterol-focused mechanism may provide a long-sought unified explanation of HAND pathogenesis that takes into account all contributing factors. Evidence for the impairment by Nef of cellular cholesterol balance, potential effects of this impairment on brain cells, and opportunities to therapeutically target this element of HAND pathogenesis are discussed.

Indexed as

HIV-1HIV InfectionsBrainCholesterolHumansnef Gene Products, Human Immunodeficiency VirusCholesterolnef Gene Products, Human Immunodeficiency Viruscholesterolepigenetic modificationsextracellular vesiclesHANDHIVinflammationlipid raftsNeftrained immunity

Identifiers

PMID37942865
PMCPMC11032165
OpenAlexW4388529209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.